This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MDCO-700

The Medicines Company

Drug Names(s): ABP700, ABP-700

Description: ABP-700 is a positive allosteric modulator of the y–aminobutyric acid (GABA) receptor, a ligand-gated ion channel. Its mechanism of action is via potentiation of GABAA receptor activation, which leads to its sedative and anesthetic effects. ABP-700 contains an ester that is designed to undergo rapid hydrolysis in the body by nonspecific tissue esterases that produce an inactive metabolite. This mechanism of deactivation results in a rapid and predictable offset profile

Deal Structure: Annovation and Medicines Company
In July 2014, The Medicines Company announced that it has an exclusive option to acquire worldwide rights for ABP-700 on predetermined terms.

In January 2015, The Medicines Company exercised its option to acquire Annovation Biopharma (ABP-700). In February 2015, The Medicines Company completed its acquisition of all of the outstanding equity of Annovation Biopharma.


MDCO-700 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug